Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:04:34 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:PBYI - PUMA BIOTECHNOLOGY INC - http://www.pumabiotechnology.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PBYI - Q0.13.91·5.120.55.02+0.142.9167.47491,8734.87  5.11  4.877.73  2.1319:34:47Apr 1815 min RT 2¢

Recent Trades - Last 10 of 1873
Time ETExPriceChangeVolume
19:34:47Q5.120.2410
16:00:00Q5.020.1438
16:00:00Q5.020.14100
16:00:00Q5.020.1474
16:00:00Q5.020.141,044
16:00:00Q5.020.14365
16:00:00Q5.020.1454
16:00:00Q5.020.141
16:00:00Q5.020.14212
16:00:00Q5.020.1466

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 16:15U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
2024-04-03 17:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-03-20 08:30U:PBYINews ReleasePuma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
2024-02-29 16:05U:PBYINews ReleasePuma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-27 18:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2024-02-22 16:10U:PBYINews ReleasePuma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference
2024-02-15 16:10U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 08:30U:PBYINews ReleasePuma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
2024-01-11 16:07U:PBYINews ReleasePuma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
2023-12-11 08:30U:PBYINews ReleasePuma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
2023-11-06 17:15U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 16:05U:PBYINews ReleasePuma Biotechnology Reports Third Quarter 2023 Financial Results
2023-10-19 16:14U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
2023-10-14 12:30U:PBYINews ReleasePuma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
2023-10-04 17:30U:PBYINews ReleasePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2023-09-21 16:10U:PBYINews ReleasePuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
2023-08-31 16:07U:PBYINews ReleasePuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-08 08:30U:PBYINews ReleasePuma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
2023-08-03 16:05U:PBYINews ReleasePuma Biotechnology Reports Second Quarter Financial Results
2023-07-20 16:15U:PBYINews ReleasePuma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results